Transparency and reproducibility in data analysis: the Prostate Cancer Prevention Trial

Author： Baker Stuart G.   Darke Amy K.   Pinsky Paul   Parnes Howard L.   Kramer Barnett S.  

Publisher： Oxford University Press

ISSN： 1465-4644

Source： Biostatistics, Vol.11, Iss.3, 2010-07, pp. : 413-418

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Prostate stromal cell telomere shortening is associated with risk of prostate cancer in the placebo arm of the Prostate Cancer Prevention Trial

By  

THE PROSTATE, Vol. 75, Iss. 11, 2015-08 ,pp. : 1160-1166

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Use of the Finasteride-Adjusted Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator in a Mexican Referral Population: A Validation Study

By  

Urologia Internationalis, Vol. 89, Iss. 1, 2012-05 ,pp. : 9-16

Karger

Access to resources Recommend Favorite

Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial

By  

THE PROSTATE, Vol. 75, Iss. 13, 2015-09 ,pp. : 1403-1418

John Wiley & Sons Inc

Access to resources Recommend Favorite

Multiparametric magnetic resonance imaging outperforms the Prostate Cancer Prevention Trial risk calculator in predicting clinically significant prostate cancer

By  

CANCER, Vol. 120, Iss. 18, 2014-09 ,pp. : 2876-2882

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Prostate Cancer Prevention Trial risk calculator and the relationship between prostate‐specific antigen and biopsy outcome

By  

CANCER, Vol. 119, Iss. 16, 2013-08 ,pp. : 3007-3011

John Wiley & Sons Inc

Access to resources Recommend Favorite